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ABSTRACT 
  
 While Argentina has significantly improved access to HIV care and antiretroviral 
therapy (ART) for both the general population and prisoners, the prevalence of alcohol 
use disorders (AUDs) among HIV-infected prisoners and their relationship to accessing 
ART in Argentina is currently unknown. This study aims to characterize the substance 
abuse patterns of HIV-infected prisoners in Argentina and to assess the independent 
correlates of receipt of pre-incarceration ART.  
 An anonymous, cross-sectional survey of 100 HIV-infected federal prisoners was 
conducted in the Buenos Aires municipality from July-December 2010. AUDs were 
assessed using the AUDIT scale. 
 A majority (63 per cent) of participants met criteria for AUDs, 45 per cent of 
subjects were diagnosed with HIV in prison and one-quarter had initiated ART during 
the current incarceration. In addition, over one-third (35 per cent) of participants did not 
receive ART during the pre-incarceration period despite receiving it upon incarceration. 
This correlated significantly with the presence of having an AUD (AOR 0.20, 95 per cent 
CI 0.06-0.74, p = 0.016). 
AUDs are prevalent among HIV-infected prisoners in Argentina and are 
significantly related to not receiving ART in the community among those who meet 
treatment criteria and receive ART in prison. While Argentina has provided an exemplary 
model of HIV-related health care reform within its prisons, future efforts to provide 
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screening and treatment for AUDs are needed to improve the health of the nation’s 
incarcerated population.  
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INTRODUCTION 
Similar to the global pandemic, HIV and incarceration are closely intertwined in 
Argentina. While 0.6% of Argentina’s general population are estimated to be people 
living with HIV/AIDS (PLWHA), HIV is more than seven times more prevalent within 
its prisons compared to the general population (Oficina de las Naciones Unidas Contra la 
Droga y el Delito (ONUDD) 2009). As HIV testing is not mandatory, this represents the 
minimum prevalence of HIV among prisoners.  In the past ten years, the number of 
known PLWHA in Argentina’s federal prisons has ranged from 364 to 747, with 
approximately ten deaths from AIDS each year (ONUDD 2009). As of May 2008, there 
were approximately 260 people living with HIV and 93 people living with AIDS in 
federal prisons in Argentina, and approximately half were reported to have received 
antiretroviral therapy (ART) (ONUDD 2009). 
Over the past decade, Argentina has greatly increased both de jure and de facto 
access to health care for PLWHA. These improvements in health care have been well 
characterized within the general population. By providing universal free ART to PLWHA 
who meet international treatment guidelines, Argentina has dramatically improved access 
to ART for HIV-infected patients in the general population from <10% in 2005 to 70% 
in 2007, and access to ART has remained steady through 2010 (Joint United Nations 
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Programme on HIV/AIDS (UNAIDS) 2008; World Health Organization (WHO), 
UNAIDS et al. 2010).  
In addition to these recent improvements in health care access within the general 
community, the Ministry of Justice, Security, and Human Rights has worked over the 
past ten years in order to improve access to primary health care and psychosocial services 
within prisons in the Argentine Federal Penitentiary Service (FPS). As recently as 2003, 
federal prisons in Argentina were plagued by overpopulation and recurring violence. 
Since that time, the prisons have raised their standards for basic medical care, upgraded 
their medical equipment, and launched a number of successful health campaigns such as 
mass vaccinations for influenza, yellow fever, and tetanus. Argentina has also created 
rehabilitation centers within several federal prisons for people who use illicit drugs, as 
well as ambulatory treatment programs for individuals with dual diagnoses. 
Furthermore, Argentina has developed programs that allow mothers to care for their 
children while in prison, including powdered formula distribution and parenting 
workshops for inmates (Arcuri 2010).   
As part of this blanket improvement in prisoner healthcare over the past decade, 
Argentina has greatly expanded the services offered to inmates living with HIV/AIDS. 
This expansion of care is enshrined in national legislation that mandates the right to 
psychosocial and medical services for incarcerated populations and includes provisions 
guaranteeing access to HIV treatment throughout the duration of incarceration  (Arcuri 
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2010; El Senado y Cámara de Diputados de la Nación Argentina 1996). Voluntary, 
confidential HIV testing is provided for new prisoners, as well as for those who show 
clinical symptoms of AIDS or are diagnosed with HIV-associated medical co-morbidities 
(Arcuri 2010). Those with HIV receive special diets, and pregnant inmates with HIV 
have universal access to ART to prevent vertical transmission (ONUDD 2009).  
In spite of these remarkable efforts, however, there remains room for 
improvement in the delivery of health care for PLWHA within prisons and communities 
in Argentina. Specifically, there is an unmet need for interventions focusing on the 
treatment of alcohol use disorders (AUDs) among prisoners living with HIV/AIDS in 
Argentina, owing to a dearth of research on the subject. This is an important line of 
investigation, given both the prevalence of alcohol use among the general population in 
Argentina, as well as the well-documented relationship in other countries between AUDs 
and adverse health outcomes (Azar 2010).  
Alcohol consumption is widespread in Argentina. A survey of the general 
population found that greater than 80% of respondents had consumed alcohol in the past 
year, greater than 50% of respondents had consumed alcohol in the past month, 11.6% 
of respondents met criteria for harmful drinking using the alcohol use disorders 
identification test (AUDIT), and 34.5% of male respondents between the ages of 18-29 
had had alcohol-related health problems in the past year (Munné 2005). Similarly, a 
survey of 500 MSM in Buenos Aires found that 78% of participants had consumed 
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alcohol in the previous two months, while 25% of participants were considered to be 
“heavy drinkers” (defined as consuming alcohol at least once per week and usually to the 
point of “feeling it a lot”, “getting drunk” or “feeling like they might pass out”) (Balan, 
Carballo-Dieguez et al. 2013).  
Although alcohol is legal in Argentina as in most other countries worldwide, 
excess alcohol consumption can result in serious negative consequences for both 
individuals and for society. Multi-criteria decision analysis modeling has shown alcohol 
to be the most harmful drug of abuse worldwide when accounting for its consequences to 
both individual users and society at large, and it ranks as the fourth most-harmful 
substance to individual users behind heroin, crack cocaine, and methamphetamine (Nutt, 
King et al. 2010). Further research has found alcohol to be causally linked to both acute 
and chronic disease outcomes affecting nearly all of the body’s organ systems (Rehm, 
Baliunas et al. 2010). 
Along with health problems directly caused by alcohol consumption, AUDs are 
associated with numerous negative secondary HIV prevention outcomes. AUDs are 
associated with decreased ART adherence in prospective and cross-sectional research 
among the general population of PLWHA (Azar, Springer et al. 2010; Hendershot, 
Stoner et al. 2009; Mellins, Havens et al. 2009), as well as among HIV-infected 
incarcerated populations (Springer, Azar et al. 2011).  
	   5	  
In addition to their association with decreased ART adherence, AUDs have been 
shown to accelerate liver disease in PLWHA, owing to both the hepatotoxic effects of 
alcohol as well as the increased hepatotoxicity in conjunction with ART (Springer, Azar et 
al. 2011). The hepatotoxic effects of alcohol on PLWHA are of particular concern as 
death from liver disease is the most frequent non- AIDS-related cause of mortality among 
PLWHA in the United States (Weber, Sabin et al. 2006). Furthermore, 30% of PLWHA 
in the United States are co-infected with HCV (Soriano, Sulkowski et al. 2002), and 
even low levels of alcohol consumption among individuals with HCV-associated hepatic 
steatosis significantly increases their risk of progression to hepatic fibrosis (Serfaty, 
Poujol-Robert et al. 2002). 
Along with its deleterious effects on secondary HIV prevention, alcohol use is also 
strongly associated with factors related to primary HIV prevention as well (Springer, Azar 
et al. 2011). Specifically, alcohol use increases high-risk HIV transmission behaviors, as 
shown by research in both the United States and throughout Latin America. Among male 
inmates aged 18-29 in the United States, those who drank heavily were at greater risk to 
report unprotected sex with multiple partners in the three months prior to incarceration 
than those who did not (odds ratio [OR], 1.68, 95% confidence interval [CI], 1.11-
2.54). (Ludford, Vagenas et al. 2013; Margolis, MacGowan et al. 2006; Springer, Azar 
et al. 2011; Vagenas, Ludford et al. 2013). Similarly, a recent systematic literature 
review of thirty articles pertaining to alcohol use and high-risk sexual behavior in Latin 
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America found that fourteen of the articles demonstrated direct associations between 
alcohol use and unprotected sex, while another thirteen provided indirect links between 
the two (Vagenas, Lama et al. 2013). Furthermore, research conducted among 
seropositive, sexually-active MSM in Lima, Peru found that the presence of an AUD was 
independently correlated with high-risk sexual behaviors in the previous six months, 
incuding: >5 sexual partners, presence of an STI, being a sex worker, unprotected sex 
during last encounter, and having sex with a seronegative partner. The associations 
between these variables and AUDs significantly increased with severity of the AUD 
(Ludford, Vagenas et al. 2013). In addition, seropositive Peruvian MSM with an AUD 
were more than twice as likely as those who did not meet AUD criteria to be unaware of 
their HIV status (Vagenas, Ludford et al. 2013). 
AUDs are chronic relapsing conditions that are seldom sufficiently treated by 
forced abstinence provided in criminal justice settings.  As such, individuals with AUDs 
have a high likelihood of relapse soon after release, and effective treatment is crucial to 
maintaining the benefits of ART afforded within the structured settings of prisons and 
optimizing longitudinal health outcomes upon release to the community (Copenhaver, 
Chowdhury et al. 2009; Springer, Azar et al. 2011).  
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STATEMENT OF PURPOSE, SPECIFIC AIMS, AND HYPOTHESES 
Statement of Purpose and Specific Aims 
In order to address this knowledge gap regarding AUDs among HIV-infected prisoners 
in Argentina, this study characterizes their prevalence among 100 HIV-infected 
prisoners. Because prisons are structured settings that can effectively screen and treat 
chronic conditions, this study examine factors associated with receipt of ART within the 
prison setting compared to a lack of receipt in the period immediately before incarceration 
where such structure may not have existed.   
 
Hypotheses 
• Given the widespread prevalence of alcohol use in Argentine society, there will be 
a high prevalence of AUDs among prisoners with HIV/AIDS in Buenos Aires. 
• Given the recent efforts to improve the quality of medical care within Argentina’s 
prison system, the controlled nature of the prison environment, and prior research 
that demonstrates decreased adherence to ART among individuals with AUDs in 
other settings, there will be a positive association between AUDs and improved 
receipt of ART within prisons in Buenos Aires.  
• Factors that will relate to accessing HIV/AIDS-related care in the community will 
include: HIV/AIDS-related stigma, substance use disorders, mental health, and 
level of social support.  
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METHODS 
Study Design 
Data were collected from July 2010-January 2011 through an anonymous, cross-
sectional study conducted at federal prisons near Buenos Aires, Argentina. A 
comprehensive study questionnaire was designed to assess the following parameters 
using standardized metrics:  
• Drug abuse severity using the DAST-10 (Skinner 1982; Gavin, Ross et 
al. 1989). This is a brief instrument designed to quantitatively evaluate 
severity of substance use through a set of twenty-eight self-reported 
questions. Initial research found that it maintained internal consistency 
and reliability, and it has subsequently become a widely used metric in 
addiction research. 20- and 10-item versions of the DAST have also been 
developed, both of which maintain high internal consistency and 
reliability, as well as strong correlation with the original 28-question 
metric. The Spanish-language version of the DAST-10 metric used for 
this study was developed by a team of researchers from the Yale School of 
Medicine’s Clínica Hispana and Nova Southeastern University and was 
validated among native Spanish-speakers in South Florida. Like the 
original English version, the Spanish version of this assessment was found 
to maintain internal reliability and to accurately differentiate users of illicit 
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drugs from non-substance users and from individuals with AUDs  
(Bedregal, Sobell et al. 2006). 
• AUDs using the AUDIT (Saunders, Aasland et al. 1993). The AUDIT is a 
ten-item questionnaire developed through a six-country World Health 
Organization collaborative project that assesses alcohol consumption, 
alcohol-related behaviors, and alcohol-related problems. The Spanish-
language version of the AUDIT used in this study was previously validated 
among adults in Spain and was found to maintain high criterion-related 
validity when compared to clinical diagnoses of alcohol abuse or 
dependence as defined by DSM-IV and ICD-10 (de Torres, Rebollo et al. 
2009). Of note for clinicians, this is a useful research tool that can be used 
to screen for alcohol dependence but is not a diagnostic instrument. 
• Social support using the Multidimensional Scale of Perceived Social 
Support (MSPSS). This is a twelve-item questionnaire that subjectively 
assesses support from family, friends, and significant others, which has 
good internal and test-pretest reliability along with moderate construct 
validity (Zimet, Powell et al. 1990). Since its initial validation among a 
largely homogenous group of college students, its validity as a metric of 
social support has been confirmed among a broad range of populations 
(Canty-Mitchell and Zimet 2000). 
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• HIV-related stigma experienced by subjects using the Berger HIV Stigma 
Scale (Berger, Ferrans et al. 2001). This is a forty-question scale designed 
by Berger and colleagues that assesses perceived levels of HIV-related 
stigma. In addition to assessing global HIV-related stigma, this metric also 
contains four subscales focused on specific aspects of HIV-related stigma, 
namely: Disclosure Concerns, Personalized Stigma, Negative Self-Image, 
and Concern with Public Attitudes towards People with HIV. This survey 
utilized a Spanish-language version of the Berger Stigma Scale that was 
validated among a population of native Spanish-speakers in Peru (Franke, 
Munoz et al. 2010)  
• Major Depressive Disorder using the Patient Health Questionnaire (PHQ-
9) (Kroenke, Spitzer et al. 2001). This is a nine-item questionnaire on 
which patients provide a score of “0” (not at all) to “3” (nearly every day) 
for the 9 DSM-IV criteria of Major Depressive Disorder: depressed or 
irritable mood; decreased interest or pleasure; significant change in weight 
or appetite; change in sleep; change in activity; fatigue or energy loss; 
guilt/worthlessness; diminished concentration; thoughts of suicide/active 
suicide plan (Association and DSM-IV. 1994). Criterion validity was 
established by comparing this metric to structured mental health 
professional (MHP) interviews of 580 patients. Based on the MHP 
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interviews as gold standard, a score of PHQ-9 ≥10 was found to have 
88% sensitivity and 88% specificity for Major Depressive Disorder. 
Subsequent research on young mothers in Honduras found that the 
Spanish-language version of the metric had a sensitivity of 77% and a 
specificity of 100% for diagnosis of Major Depressive Disorder compared 
with findings from structured clinical interviews (Wulsin, Somoza et al. 
2002). 
In addition to the standardized metrics above, the subjects were asked a series of 
questions written specifically for this survey to assess the following: background 
demographics, criminal justice history, substance use history, barriers to community re-
entry upon release (Choi, Kavasery et al. 2010), medical co-morbidities, access to 
medical services, HIV-related risk behaviors in the period prior to incarceration, and 
access to HIV-related medical and social services both prior to and during the current 
period of incarceration. 
This questionnaire was created in English and then translated into Spanish, using 
previously validated Spanish-language versions of the study metrics when available. The 
remainder of the study form was translated and back translated (Brislin 1970) by 
bilingual research assistants in the United States and further modified for the local 
context by research staff at the Fundación Huésped in Buenos Aires. 
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Data Collection 
After receiving ethical approval from both the Yale University School of Medicine 
Human Investigations Committee in New Haven, CT, USA and the Committee of 
Bioethics at the Fundación Huésped in Buenos Aires, Argentina, subjects were 
sequentially selected for participation in the study. The study was conducted at the 
federal prison complex in Florencio Varela, Buenos Aires, Argentina in all five on-site 
units. All inmates with documented HIV-positive status and sufficient mental capacity to 
provide informed consent were eligible for participation in the study. HIV-positive status 
was determined using lists maintained in the medical office of the incarceration facility. 
Prison medical staff aware of a prisoner’s HIV status asked if they were interested in 
participation.  Interested inmates were then approached by research staff who explained 
the informed consent and enrollment procedures. Subjects were provided with both a 
written and oral explanation of the research study and were informed that there were no 
incentives or disincentives for their participation. In addition, subjects were informed that 
their individual response forms would be coded anonymously without any identifying 
information and that their answers would not be shared with the staff at the prison. After 
providing oral consent, subjects were interviewed individually in private offices by 
trained research assistants. All interviews were conducted in Spanish without the use of a 
translator, with the exception of one subject who had spent his childhood in North 
America and preferred to complete the interview in English.    
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Data Analysis 
In total, all eighty-two individuals on the HIV registry at the Florencio Varela 
prison during the months of July and August 2010 were considered for participation in 
the study. Two individuals were excluded due to misidentification of their HIV status on 
the official registry, fourteen chose not to participate in the study, and five others were 
not able to participate as they were not on location at the prison facility at the time the 
interviews were conducted. A total of sixty-one individuals were enrolled in the study at 
the Florencio Varela prison, one of who subsequently chose not to complete the 
interview. Subsequently, forty more individuals from units within the federal prison in La 
Plata, Berisso, and Ensenada were enrolled in the study from October-December 2010 
for a total of one hundred participants [Figure].  
Individual survey responses were then coded and analyzed using SPSS v.19.0 
(SPSS Inc., Chicago, IL) with the assistance of a trained biostatistician, Jeffrey 
Wickersham, Ph.D. Summary statistics of demographics, prevalence of substance abuse, 
and high-risk HIV behavior were assessed through variable count functions. In addition, 
a bivariate regression was performed using receipt of ART upon incarceration but not in 
the 30 days pre-incarceration as the dependent variable. For this study, these subjects 
were considered as having not received appropriate ART therapy in the period 
immediately prior to incarceration because they did not receive ART during that period 
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despite having been found to meet ART treatment guidelines upon incarceration. This 
group was compared to the remaining subjects, who were either on ART pre-
incarceration or who had never initiated on ART in either setting because they did not 
meet the ART treatment guidelines used within the prison.  
AUDs, drug abuse severity, HIV-related stigma, age, duration of present 
incarceration, previous diagnosis of tuberculosis, and mental illness were used as 
independent variables.  Statistical significance was defined as two-tailed P <0.05. Alcohol 
use disorders were assessed with the AUDIT, and scores were stratified for bivariate 
analysis into two categories [Low Risk or sensible drinking (score <8 for men or <4 for 
women) vs. Hazardous Drinking or Alcohol Dependence (score of ≥8 for men or ≥4 for 
women)] (Miller, Zweben et al. 1992). This is in keeping with the stratification used by 
the initial validation study of the AUDIT metric, which found that 92% of individuals 
who received a clinical diagnosis of hazardous or harmful patterns of alcohol use had an 
AUDIT score ≥8, while 94% of individuals found clinically to exhibit non-hazardous 
patterns of alcohol use had AUDIT scores <8 (Saunders, Aasland et al. 1993).  Drug 
abuse severity was assessed with the DAST-10. Given the relatively small sample size, 
responses were stratified for bivariate analysis into two categories [No-Moderate 
Reported Problem (score <6) vs. Substantial or Severe Problem (score of ≥6)]. Major 
depressive disorder was screened for using the PHQ-9 and defined as a score of >9. 
Subjects were also asked specifically if they had received prior treatment for mental 
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illness. Social support and HIV-related stigma were assessed using the Berger HIV 
Stigma Scale and the Zimet Social Support Scale, respectively, and the resultant scores 
were used as continuous variables in the bivariate analysis.  
Correlations with appropriate ART in the thirty days before incarceration were 
examined using logistic regression modeling with all variables that met threshold of <0.2 
at the bivariate level in a multivariate model examining the correlates associated with the 
dependent variable.  
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RESULTS 
The characteristics of the sample are detailed in Table 1.  Consistent with the 
demographics of the general prison population, the study participants were 
predominantly male. Of note, the study did include one transgender participant. In 
general, study subjects were serving multi-year sentences for non drug-related crimes. All 
subjects had some degree of formal schooling, although half had not completed 
secondary education. 
  Many of the subjects also had significant medical and psychological co-
morbidities. There was a significant prevalence of Hepatitis B and C among the study 
participants, and nearly one third had been diagnosed with tuberculosis. The anonymous 
nature of the study precluded a medical chart review, so this information was obtained via 
self-report.   
 AUDS and illicit substance use were widespread among the study participants. 
Nearly 2/3 of study participants met criteria for hazardous drinking or alcohol 
dependence per AUDIT screening guidelines. In addition, nearly half of the study 
participants had used cocaine in the 30 days prior to incarceration, and 1/5 of 
participants had used benzodiazepines recreationally during that same period. Of note, 
while nearly half of the study participants reported having a lifetime history of IDU, only 
2% of study participants reported IDU in the period immediately prior to the current 
incarceration.  
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In general, participants reported widespread access to HIV-related medical 
services in prison. Nearly half of the subjects were diagnosed with HIV in prison, either 
previously or during the present incarceration, and one-quarter of the study participants 
had initiated ART during the current incarceration. In addition, nearly all participants felt 
confident they could continue to receive HIV-related medical care upon release. In spite 
of this, approximately one third (35%) of participants did not receive ART in the month 
prior to their incarceration despite meeting criteria for ART used within the prison 
setting and receiving ART during the current incarceration. Of note, three subjects who 
received ART in the 30 days prior to incarceration reported that it was not continued in 
prison.  
Bivariate correlations with appropriate ART in the thirty days before incarceration 
were examined in order to create a multivariate model [Table 2].  In the final model, only 
the presence of AUDs (AOR=0.20, 95% CI 0.06-0.74, p=0.016) and duration of 
present incarceration (AOR=0.98, 95% CI 0.97-0.99, p=0.047) were significantly 
associated with receiving ART after incarceration, but not in the 30 days before. 
Specifically, presence of an AUD per AUDIT screening guidelines or increased duration 
of present incarceration correlated positively with inappropriate ART in the 30 days prior 
to incarceration. Lower social support, however, approached statistical significance in the 
final model (AOR=0.95, 95% CI 0.91-1.00, p=0.054).  
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DISCUSSION 
 
Prevalence of AUDs among PLWHA within Argentina’s Prisons: Implications for 
Prevention and Treatment 
This study is the first to illustrate the widespread prevalence of alcohol use 
disorders (AUDs) among HIV-infected prisoners in Argentina and provide evidence 
showing the significant relationship between AUDs and secondary prevention of HIV in 
this population. The prevalence of AUDs among this sample is over five times that of the 
general Argentine population (Munné 2005). Furthermore, AUDs correlated 
significantly with decreased ART use prior to incarceration in multivariate logistic 
regression. This potentially suggests a need for improved access to treatment for AUDs 
not only in the community before incarceration, but for this sample, treatment of AUDs 
during incarceration and part of post-release transitional programs in Argentina. 
Research from other countries suggests that there are insufficient substance abuse 
treatment programs in prisons despite a clear, overwhelming need (Chandler, Fletcher et 
al. 2009; Hendershot, Stoner et al. 2009; Meyer, Chen et al. 2011).  
The high prevalence of AUDs among the HIV-infected Argentine prison 
population could potentially be addressed through increased routine screening for AUDs 
upon incarceration using previously validated instruments (Cremonte and Cherpitel 
2008), as well as through the development of culturally appropriate AUD treatment 
programs within prisons. Since AUDs are chronic relapsing conditions seldom 
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sufficiently treated by the forced abstinence philosophy prevailing in criminal justice 
settings, effective treatment is crucial to maintaining the benefits of ART afforded within 
the structured settings of prisons and optimizing longitudinal health outcomes upon 
release to the community (Springer, Azar et al. 2011). Pharmacologic therapy with 
naltrexone is the AUD treatment modality best supported by current evidence (Anton, 
O'Malley et al. 2006; Altice 2010). Acamprosate, another pharmacological therapy used 
for AUD treatment, has been found to be less effective than naltrexone but equivalent to 
counseling alone (Anton, O'Malley et al. 2006; Mason, Goodman et al. 2006), and the 
use of disulfiram for treating AUDs is precluded by its hepatotoxic effects. By contrast, 
behavioral interventions have been found to have small to modest effects on treating 
AUDs.  
Given these findings, naltrexone therapy offers much promise for improving the 
health and well being of PLWHA who meet criteria for AUD diagnosis.  Studies 
examining the efficacy and safety of extended-release naltrexone are currently underway 
among HIV-infected men in Peru and among HIV-infected prisoners with AUDs 
transitioning to the community in the United States. Results from these studies could 
potentially serve as the basis for a similar program development in Argentina and 
elsewhere [Springer & Altice, www.clinicaltrials.gov, NCT01077310; Duerr, Lama, & 
Altice, www.clinicaltrials.gov, NCT01377168]. Such an intervention would likely have 
both primary and secondary preventative effects, given the strong association between 
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AUDs and high-risk sexual behavior throughout Latin America (Ludford, Vagenas et al. 
2013; Vagenas, Lama et al. 2013; Vagenas, Ludford et al. 2013). Further research is 
also needed to characterize the connection between AUDs and insufficient treatment with 
ART within the community for PLWHA who are incarcerated in Argentine prisons. 
In addition to the use of pharmacotherapy, there is growing interest in the use of 
complimentary and alternative medicine (CAM) for treating addition. A review of 
evidence-based literature published in the past thirty years in English, Korean, Japanese, 
and Chinese on the use of acupuncture for treatment of AUDs, however, found that the 
results of these studies is equivocal and marred by poor adherence to the methodological 
criteria in the Cochrane Handbook (Cho and Whang 2009; Higgins, Green et al. 2008).  
The use of randomized controlled trials as a gold standard, however, is based on 
several theoretical premises that are problematized in the study of acupuncture and other 
forms of CAM that have not yet been integrated into western clinical practice. The 
efficacy of some forms of CAM may be due to a number of synergistic factors that have 
each been shown to have strong effects on patients, thus problematizing the design of a 
true placebo. Furthermore, a true randomization of patients with a given medical 
diagnosis to either control or experimental arms of a CAM study would conversely work 
against the goal of minimizing bias, as this approach would fail to account for the a priori 
heterogeneity of expectations and beliefs regarding this treatment modality (Wayne and 
	   21	  
Kaptchuk 2008; Wayne and Kaptchuk 2008; Wang, Schmid et al. 2010; Yeh, Kaptchuk 
et al. 2010).  
Regarding acupuncture specifically, there is a wide degree of variation in is 
practice. Thus, research trials that attempt to standardize the acupuncture session by 
mandating factors such as loci of needle placement, and duration of stimulation do not 
accurately reflect acupuncture as practiced in situ. Furthermore, trials that utilize “sham” 
acupuncture involving the stimulation of “inactive” points or the use of retractable 
needles that do not penetrate the skin, remains controversial as a valid control (Lund and 
Lundeberg 2006), as factors such as depth and location of needle placement, as well as 
the number of needles placed, vary greatly between styles of acupuncture and between 
different providers of the same style of treatment. There is even intra-provider 
heterogeneity of practice depending on the specific needs of a given patient (Langevin, 
Wayne et al. 2011). 
 
Patterns of Substance Use: Implications for Harm Reduction Practices in Argentine 
Prisons 
The patterns of drug abuse among the study population are different than those 
found among incarcerated populations in other middle-income countries (Azbel, 
Wickersham et al. 2012; Dolan, Kite et al. 2007). Specifically, this study found an 
overwhelming predominance of cocaine abuse among the study population, as well as a 
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significant degree of benzodiazepine abuse. In contrast with previously reported studies 
of prisoners in other middle-income countries, however, hardly any of the subjects in this 
investigation reported using opioids. A study of 402 prisoners in Ukraine, for instance, 
found that in the thirty days prior to incarceration, 34.4% of participants had used 
opioids, 21.1% had used amphetamines, 20.5% had combined opioids with hazardous 
drinking, and 15.4% had combined opioid use with amphetamine use. Furthermore, 
56.6% of the participants in the study met criteria for hazardous drinking and 48.7% had 
a lifetime history of IDU (Azbel, Wickersham et al. 2012). Another recent investigation 
of 97 HIV-infected persons recently released from prison in Ukraine found that 56.7% of 
study participants reported injection drug use while in prison, of whom 74.1% reported 
sharing injection equipment (mean of 4.28 sharing partners, mean of 4.43 uses per 
needle) (Izenberg, Bachireddy et al. 2013). 
The substance use patterns found among our study participants are, however, 
consistent with nationwide patterns of drug abuse within Argentina. A study of 500 
MSM in Buenos Aires, for instance, found that approximately 40% of participants 
reported a lifetime history of cocaine use and 30% reported using it in the previous two 
months, while approximately 20% of participants reported a lifetime history of pasta base 
or tranquilizer use and 15% reported using these substances in the previous two months. 
In contrast, less than 5% of study participants reported using the other substances 
assessed, including heroin/opioids, ecstasy, methamphetamines, hallucinogenics, 
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inhalants, and amyl nitrite (“poppers”) (Balan, Carballo-Dieguez et al. 2013). 
Furthermore, cross-sectional research conducted in Buenos Aires, Argentina and 
Montevideo, Uruguay among individuals who had never injected drugs but had sniffed, 
snorted, or smoked illicit substances in the previous ninety days found that 91.7% of 
participants had used cocaine (80.4% via inhalation, 6.9% via smoking coca paste, and 
1.1% via smoking crack), while only about 5% of participants reported using lysergic 
acid diethylamide (LSD), heroin, glue, or morphine during that same time period 
(Caiaffa, Zocratto et al. 2011).  
In addition, while injection drug use was initially the primary route of HIV 
transmission in Argentina at the outset of the HIV epidemic (Rodriguez, Marques et al. 
2002) and nearly half of our research subjects reported a lifetime history of IDU, almost 
none of the subjects in this study had injected drugs in the month prior to the current 
incarceration. The high prevalence of remote drug injection and the long history of 
incarceration among this population likely explain the high prevalence of viral hepatitis in 
spite of little recent injection drug use. Lifetime history of IDU among our study 
participants was higher than the prevalence of IDU (31%) among seropositive inmates in 
a study conducted in 2001 within a federal penitentiary in Buenos Aires but was half that 
reported in prior research conducted among HIV-positive prisoners in Argentina in the 
1990’s (Dolan, Kite et al. 2007; Troncoso, Palmero et al. 2004). This finding is 
consistent with patterns found among the Argentine population outside of prison, 
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namely that the prevalence of injection drug use (IDU) and the sharing of injection 
equipment have decreased since the 1990’s (Cohen 2006; Rossi 2006), leading to a 
sharp decrease in the percentage of new HIV infections secondary to IDU in Argentina 
(Mendes Diz, Camarotti et al. 2008; Programa Nacional de Lucha contra el Retrovirus 
del Humano 2008).  
These findings of minimal levels of IDU among study participants suggest that 
future efforts should focus on sexual transmission. Although our study did not inquire 
regarding high-risk behavior within the prison, prior research among seropositive 
inmates within a federal penitentiary in Buenos Aires found that 66% of subjects had had 
multiple sexual partners in the past year (of whom 60% never used a condom), and 27% 
reported being the victim of sexual assault. Furthermore, none of our study participants 
admitted to having same-sex relations before incarceration, but prior research focused on 
sexual behavior among seropositive inmates in an Argentine federal penitentiary found 
that nearly ¾ of the subjects had engaged in homosexual activity within the previous 
twelve months, of whom half had first engaged in this activity while in prison (Troncoso, 
Palmero et al. 2004). To that end, Argentine law stipulates access to condoms for all 
inmates regardless of whether or not they receive conjugal visits (Programa Nacional de 
Lucha contra el Retrovirus del Humano 2008). If universally available, such programs 
may prevent intra-prison HIV transmission.  While few prison facilities have initiated 
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such programs themselves, several prisons have allowed for nongovernmental 
organizations (NGO’s) to provide government-issued condoms to inmates.  
 
Other Findings and Limitations 
In addition to the presence of AUDs, increased duration of incarceration was 
significantly associated with receiving ART during the present incarceration but not in 
the 30 days beforehand. Though this particular study was unable to elucidate the reasons 
behind this association, one explanation is the improved access to ART in the community 
in Argentina over the past decade, which would have increased the likelihood that 
individuals who were incarcerated more recently would have received ART prior to 
incarceration. Another possible explanation is that the study subjects were at increased 
likelihood of meeting criteria ART initiation criteria after a prolonged period of 
incarceration. Further research is needed to explore the mechanism underlying this 
association.  
This study did have a number of limitations. Ideally, we would have defined 
eligibility for ART use based on CD4+ lymphocyte counts, but the lack of available 
clinical data made this impossible, thus requiring us to construct the dependent variable 
based on the expectation that anyone who was eligible for and could tolerate ART would 
receive it in prison. In addition, the relatively small sample size could have potentially 
decreased the power to detect a larger number of significant associations, as well as the 
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applicability of the study results to all HIV-infected prisoners. Of note, the study did not 
find a significant relationship between the use of other substances and secondary 
prevention of HIV. This is potentially due to either the relatively small size of our sample 
or to the widespread prevalence of AUDs, which could have overshadowed the 
relationship between other substances and the dependent variable.  Moreover, while 
social support was found to be associated with the primary outcome of accessing ART 
during incarceration but not beforehand, the relatively small sample size may have been 
insufficient to truly disentangle this association.  Prior research has, however, 
demonstrated stronger correlations between social support and adherence to ART 
(Ammassari, Trotta et al. 2002; Gonzalez 2004; Gordillo, del Amo et al. 1999; Simoni, 
Frick et al. 2006), but its association on accessing ART remains undocumented. These 
findings here suggest a need for further research on the relationship between social 
support and access to and receipt of ART in community settings among a larger sample 
size in Argentina.  
In addition, the data could not be stratified by gender owing to the small number 
of female subjects, which reflect the lower rates of incarceration of women. While women 
have traditionally had decreased access to ART, it was not possible to perform such 
analyses with the present data. Furthermore, the cross-sectional nature of the study 
precludes the inference of causality between AUDs and receiving ART upon incarceration 
but not in the pre-incarceration period. This can be addressed through further research 
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using a prospective, longitudinal design. Such a study could also examine the correlates 
with appropriate ART during the post-incarceration period of transition back into the 
community.  
In order to maintain the anonymity of the subjects, the survey relied on subjective 
reports regarding access to HIV medication and was not verified with objective medical 
records that could have demonstrated the medical outcomes of ART initiation in prison, 
namely changes in CD4 counts and viral loads. Similarly, self-reported medical co-
morbidities could not be verified by objective medical records. Assuming that there could 
be patients in our study who have either not been screened for hepatitis and TB, are not 
aware of their diagnoses, or do not care to share these diagnoses with others, the number 
of individuals with these co-morbidities reported in our sample could potentially be lower 
than the actual prevalence of these diseases in our study sample. This could be addressed 
in the future through a retrospective analysis of anonymized prison records in Argentina. 
Despite these limitations, this study does provide a unique insight into the substance 
abuse patterns and access to HIV medication among Argentine prisoners and provides a 
basis for future interventions. 
Aligning Public Health with Public Safety: Healthcare and Criminal Justice 
Consistent with prior research in prisons in the United States (Beckwith 2010; 
Springer, Pesanti et al. 2004) this study demonstrates the important role of criminal 
justice settings in the diagnosis and treatment of HIV (Altice, Mostashari et al. 2001; 
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Flanigan and Beckwith 2011) Though Argentina is a middle-income country, HIV 
treatment outcomes appear similar to those in high-income settings, likely due to its 
standardized treatment guidelines that are used in both correctional and community 
settings.  Compared to other middle-income countries, these findings are markedly better 
than reported elsewhere (Azbel, Wickersham et al. 2012; Choi, Kavasery et al. 2010; Fu, 
Bazazi et al. 2012) and could potentially serve as a model for prison health care reform in 
other middle-income countries. Three of the subjects, however, reported that they had 
received ART in the 30 days prior to incarceration but had not received it in prison. The 
reason for ART discontinuation was not explored further.  Since interruption of ART is 
associated with increased risk of HIV-related adverse events (Emery, Neuhaus et al. 
2008), it is important that the prison system in Argentina work to ensure that all inmates 
who received ART prior to incarceration continue to receive treatment while in prison.  
As nearly half of the study participants were diagnosed with HIV within prisons 
settings, this research suggests that enhanced routine HIV testing in Argentine prisons 
has succeeded in detecting a significant number of previously undiagnosed HIV cases and 
demonstrates a need for increased HIV testing of the adult population outside of the 
prison setting. Given the near-universal access to ART both within and outside of the 
prison system in Argentina, increased HIV testing would likely result in significant 
numbers of previously undiagnosed individuals with HIV receiving necessary HIV care, 
as occurred with this study population (de Voux 2012). Widespread voluntary testing of 
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the adult population would likely decrease rates of HIV transmission, as providing this 
previously undiagnosed population of PLWHA with access to ART would decrease viral 
loads and subsequently infectivity (Granich, Gilks et al. 2009). Furthermore, while 
nearly all participants in the study felt confident that they could continue to receive HIV 
care upon release, further research is needed to determine the degree to which recently 
released HIV-infected inmates are actually able to access HIV-related services and adhere 
to ART upon release.  Other studies elsewhere have suggested that this process may be 
much more difficult than our subjects anticipate (Baillargeon, Giordano et al. 2009; 
Springer, Pesanti et al. 2004) 
The findings from this study indicate that HIV-infected Argentinian prisoners not 
only have a high prevalence of AUDs but much greater access to ART than their 
counterparts in prisons located in other middle-income countries throughout the world.  
A survey conducted in Ukrainian prisons among 402 individuals being released within 
six months, for instance, found that half of those who were infected with HIV were 
unaware of their HIV status. Furthermore, 56% of these HIV-infected inmates had CD4 
<350 cells/mL but only 11% of inmates eligible for ART were receiving it (Azbel 2013). 
Another recent study conducted in Ukraine of HIV-infected individuals who had been 
released from prison within the previous year found that 67.9% of individuals on opiate 
substitution therapy and 70.4% of individuals on ART experienced an interruption in 
medication during the detention process(Izenberg, Bachireddy et al. 2013). 
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Furthermore, a similar study conducted in Malaysian prisons of 102 HIV-infected 
inmates found that while about half of the subjects reported ≥7 HIV-related symptoms, 
only two of the subjects had ever reported receiving antiretroviral medications (Choi, 
Kavasery et al. 2010).  
These findings were also confirmed by a literature review on access to ART in 
prisons in five low- and middle-income countries—China, Vietnam, Russia, Ukraine, and 
Malaysia—that found that all five countries provided either highly restrictive or no access 
to ART within their prisons. In Vietnam, prisoners were held without treatment and 
released if they were seriously ill. While such hard data is difficult to come by in Russia, 
interviews with individual patients released from a Russian prison in 2009 paint a 
harrowing picture of bureaucracy, stigma, incompetence, and poor sanitation that have 
disastrous consequences on the health and well-being of inmates infected with HIV 
(Wolfe, Carrieri et al. 2010): 
“When they brought me to the prison, I said that I had HIV and AIDS and that I 
had started taking ART because my clinical condition called for it. When I got to 
prison, I explained my situation to all the doctors who saw me, I explained, that 
having the medicines was a matter of life and death for me, and that I can’t 
interrupt the treatment. They told me to calm down…And they didn’t give me 
anything. They told me they didn’t have those medicines, they didn’t have 
connections with the AIDS Center…Basically, they were out of the loop and they 
didn’t have anything. This is how it[treatment] looked: they opened the feeding 
bunk and threw in all the pills—here you are, take it…and that’s it! The nurse 
gave the same pills to everyone—and each inmate had a different diagnosis. She 
would give us all the same pill and said, “swallow it”. They didn’t check at all if 
people were treated or not. If you come to the doctor’s office, they give you pills 
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and look in your mouth to make sure you swallow them. If you don’t swallow and 
you take a pill with you from there, you get 15 days in a punishment cell. So 
[one] guy kept eating the pills…In the end he got ascites, drum belly. And he 
died. 
 
When I got there [medical correctional facility], I told all the doctors that I had 
advanced AIDS, told them everything, showed my last medical records…But 
nothing, no effect. When I came there in 2007, many inmates with HIV had been 
transferred there and they didn’t know what to do with them. They hadn’t even 
registered us as HIV patients—we were listed as TB patients. So they put all the 
inmates with HIV in one barrack and didn’t let us out at all. I got very sick in 
spring of 2007 or 2008. I had a fever of 40oC for a whole week. The doctors 
couldn’t do anything, they couldn’t understand what was going on. At that time, 
all people with HIV had to be isolated. Even in the prison hospital, they put us in 
the isolation chamber in the basement. Can you imagine?! A punishment isolation 
chamber. The chamber I was put in was very small, about two meters long. There 
were two of us there. They didn’t do anything. For two or three weeks I sat in the 
isolation chamber and then was just sent back. They didn’t even list us people 
with HIV anywhere. Because an HIV patient in the prison means a certain diet, 
state subsidies, some additional money is supposed to be allocated for an inmate 
with HIV. And they didn’t have it. We spent one year, even more, listed as TB 
patients, not HIV patients; there was no HIV.” 
 
In contrast to such dire conditions, the prisons in Argentina play an important 
role in HIV diagnosis and delivery of HIV-related medical care. Despite the availability of 
ART both within and outside of prison in Argentina, however, this study finds that 
AUDs are a widespread problem associated with decreased use of these medications 
outside of prison among currently incarcerated HIV-infected inmates. As AUDs are 
medically-treatable conditions, it would thus be useful to design future interventions in 
Argentine prisons that provide addiction treatment services to include alcohol counseling 
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and potentially medication-assisted therapies in order to improve primary and secondary 
HIV prevention. 
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FIGURE AND TABLES 
  Figure: Participant disposit ion  
Assessed for eligibility (n= 122) 
Excluded  (n= 21) 
¨   Not meeting inclusion criteria (n= 2) 
¨   Declined to participate (n= 14) 
¨   Other reasons (n= 5) 
Enrolled in Survey (n= 101) 
Did not complete survey (n=1) 
 
Completed survey and included 
in analysis (n=100) 
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Table 1: Study Participant Characterist ics 
Background Demographics N=100 
Mean Age, years 37.6 
Gender 
     Male 
     Female 
     Transgender 
 
93 
6 
1 
Did not complete secondary education 45 
  
Criminal  Justice History  N=99 
Mean duration of present incarceration (months) 38 
Mean time remaining until release (months) 22 
Mean number of adult incarcerations 3 
Mean total lifetime spent incarcerated (years) 10.5 
  
Medical  Comorbidit ies  N=96 (%) 
Tuberculosis 30 (31%) 
     Received treatment during current incarceration 12 (12.5%) 
Hepatitis 
     Hepatitis B (n=93) 
     Hepatitis C (n=93) 
20 (22%) 
37 (40%) 
Hypertension (n=93) 23 (25%) 
  
Co-Morbid Drug Use and Mental  I l lness   
Ever diagnosed with mental illness (n=93) 6 (7%)  
Major Depressive Disorder (PHQ-9 >9) (n=95) 41 (43%) 
Alcohol Use Disorders (n=92) 
     Hazardous Drinking (AUDIT: Men 8-14; Women 4-12) 
     Alcohol Dependence (AUDIT: Men ≥15; Women ≥13) 
     Hazardous Drinking OR Alcohol Dependence 
 
21 (23%) 
36 (39%) 
57 (62%) 
Other drug use in thirty days prior to incarceration (n=100) 
     Cocaine 
     Crack/Paco 
     Opioids 
     Benzodiazepines 
 
46 (46%) 
17 (17%) 
2 (2%) 
19 (19%) 
  
HIV transmission behavior  N=93 
Injection drug use 
     Lifetime 
     In 30 days before present incarceration 
 
42 (45%) 
2 (2%) 
Mean number of unprotected sex partners in 30 days before 
present incarceration (n=92) 
 
2  
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     Partner known to be HIV-infected 
     Partner not infected with HIV or serostatus unknown 
1 
1 
Mean number of unprotected sexual encounters in 30 days before 
present incarceration (n=62) 
     Partner known to be HIV-infected 
     Partner not infected with HIV or serostatus unknown 
 
22  
9 
11 
  
HIV Care and Treatment  
Mean time since HIV diagnosis, years (N=100) 11 
First diagnosed with HIV in prison (N=100) 
     Diagnosed during current incarceration 
45 
15 
Ever saw HIV doctor or nurse  (N=99) 91  
Felt they could easily see HIV doctor after release  (N=98) 95  
Received ART upon incarceration but not in the 30 days pre-
incarceration (N=75) 
 
26 (34.7%) 
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Table 2:  Correlates of  receiving ART during present incarceration,  but not 
receiving it  in the 30 days before incarceration  
 
 
Covariate Bivariate Multivariate 
 UOR 95% C.I. P-value AOR 95% 
C.I. 
P-
Value 
Alcohol use 
disorders* 
      
    None Referent      
Hazardous or  
Dependent 
Drinking* 
0.21 0.06-0.71 0.012 0.20 0.06-
0.74 
0.016 
Duration of present 
incarceration 
0.98 0.97-0.99 0.018 0.98 0.97-
0.99 
0.047 
Social Support** 0.97 0.93-1.01 0.145 0.95 0.91-
1.00 
0.054 
Number of years 
since HIV 
diagnosis 
1.00 0.99-1.01 0.776    
Major Depressive 
Disorder (PHQ-9 
>9)+ 
0.75 0.28-2.01 0.565    
Moderate to severe 
substance abuse 
severity++ 
0.73 0.27-1.98 0.536    
Age, years 1.04 0.97-1.11 0.291    
HIV-Related 
Stigma+++ 
0.99 0.98-1.01 0.577    
AIC = 132.00, BIC = 277.51 
 
Legend: 
UOR = Unadjusted Odds Ratio, AOR = Adjusted Odds Ratio 
*Alcohol use assessed with AUDIT scale and stratified as Low Risk (men <8, women <4); 
Hazardous Drinking or Alcohol Dependence (men >8, women >4) 
**Social Support assessed with Zimet Social Support Scale 
+Mental Illness assessed with PHQ-9 Scale 
++Drug use assessed with DAST-10 scale and stratified by "no" (0), "low"(1-2), "moderate" (3-
5), "substantial” (6-8), and "severe" (9-10) problem 
+++HIV stigma assessed with Berger HIV Stigma Scale 
AIC=Akaike Information Criterion; BIC=Bayesian Information Criterion 
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